Shanghai Haiyan Pharmaceutical Technology Co., Ltd.;Yangtze River Pharmaceutical Group Co., Ltd.
发明人:
申请号：
EP16829828.9
公开号：
EP3327014A4
申请日:
2016.07.25
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
Provided is an EGFR inhibitor and a pharmaceutically acceptable salt and a polymorph thereof, and a use thereof. In particular, provided is a polymorph, a pharmaceutically acceptable salt or a prodrug of N-(2-(4-(dimethylamino)piperid-1-yl) -5-(5-fluoro-4-(1-methyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) -4-methoxy phenyl) acrylamide. In addition, also provided is a pharmaceutical composition containing the inhibitor and a use thereof.
